4 results
To evaluate the safety and activity of BB3 compared to placebo in improving renal function in the immediate post-transplant period in patientswho have received a DCD kidney transplantation.
The primary objective is to compare the percentage of patients reaching an effective FBT dose with a starting dose of 100 mcg to those with a starting dose of 200 mcg. Secondary objectives are to evaluate the safety and tolerability and the…
To evaluate the safety and activity of BB3 compared to placebo in improving renal function in the immediate post-transplant period in patients who have received a DCD kidney transplantation.
ALZ-801 is an oral agent that is being developed as a potential disease modifying treatment for AD. This 78-week Phase 3 study will focus on Early AD subjects who carry the APOE4/4 genotype, and is designed according to current regulatory guidance…